Mirum Pharmaceuticals - MIRM STOCK NEWS

Mirum Pharmaceuticals (Nasdaq: MIRM) announced that its Board of Directors granted stock options to five new employees, totaling 49,900 shares, under the 2020 Inducement Plan. The options have an exercise price of $19.81, reflecting the closing stock price on January 8, 2021. Vesting occurs over four years, with 25% vesting after one year. Mirum is focused on developing therapies for liver diseases, and its lead candidate, maralixibat, is under NDA submission for Alagille syndrome treatment. The company’s application for pediatric PFIC2 treatment is under review by the European Medicines Agency.

Mirum Pharmaceuticals (Nasdaq: MIRM) announced its participation in the J.P. Morgan Healthcare Conference, set for January 11-14, 2021. CEO Chris Peetz will discuss Mirum’s strategy and commercialization plans for maralixibat and volixibat during a presentation on January 12, from 5:20 to 6:00 p.m. ET. A live audio webcast will be accessible on the company's website. Mirum is advancing its drug pipeline for liver diseases, with maralixibat's NDA submission expected in Q1 2021 and EMA review for pediatric PFIC2 treatment underway.

Mirum Pharmaceuticals has priced its underwritten public offering of 3,750,000 common stock shares at $20.00 each, aiming to raise $75 million. A 30-day option allows underwriters to acquire an additional 562,500 shares. The offering, expected to close on December 17, 2020, will utilize proceeds for developing novel therapies targeting liver diseases. Regulatory submissions for key products like maralixibat are ongoing, with potential impacts on future market performance.

Mirum Pharmaceuticals has announced a public offering to sell $75 million in common stock, with a potential additional $11.3 million available for underwriters. The offering will be executed under a previously declared effective shelf registration statement. Leading this initiative are J.P. Morgan, SVB Leerink, and Evercore ISI as joint book-running managers. Mirum is focused on novel therapies for liver diseases, with key products like maralixibat for conditions such as Alagille syndrome and PFIC. Completion of the offering is subject to market conditions.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) has granted a stock option award of 11,300 shares to a new employee under its 2020 Inducement Plan. The options have an exercise price of $24.93 per share, vesting over four years with the first 25% on the one-year anniversary. Mirum focuses on novel therapies for liver diseases, with its lead candidate, maralixibat, in late-stage development for multiple conditions. The company is advancing a rolling NDA submission for maralixibat and has an application for PFIC2 under review by the European Medicines Agency.

Mirum Pharmaceuticals (Nasdaq: MIRM) announced a $200 million tiered, revenue-based funding agreement with Oberland Capital, inclusive of a $10 million equity investment. Milestones include $60 million by year-end 2020, $65 million upon FDA NDA acceptance for maralixibat in treating ALGS, and $35 million upon FDA approval. Mirum is advancing its rolling NDA submission for maralixibat and expects to launch in the U.S. in H2 2021. Additionally, it has submitted a marketing application to the EMA for PFIC2 treatment, validating its strategic pipeline development for rare liver diseases.

Mirum Pharmaceuticals (Nasdaq: MIRM) announced that its Marketing Authorization Application (MAA) for maralixibat, aimed at treating progressive familial intrahepatic cholestasis type 2 (PFIC2), has been validated by the European Medicines Agency. This acceptance allows the EMA to begin its review process. Maralixibat's efficacy was supported by Phase 2 INDIGO study data, which highlighted significant improvements in transplant-free survival and quality of life for patients. Additionally, a rolling NDA submission for maralixibat targeting cholestatic pruritus in Alagille syndrome has also been initiated.

Mirum Pharmaceuticals (Nasdaq: MIRM) announced its participation in upcoming virtual investor conferences. A fireside chat will be available on November 23, followed by one-on-one meetings on December 1 at the Piper 32nd Annual Virtual Healthcare Conference. The company will also present at the Evercore ISI 3rd Annual HealthCONx Conference on December 3 at 12:35 PM ET. Mirum is focused on developing therapies for liver diseases, with its lead product maralixibat in late-stage development for conditions including Alagille syndrome and progressive familial intrahepatic cholestasis.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) announced encouraging results from studies presented at the AASLD Annual Meeting, focusing on the long-term administration of maralixibat for children with Alagille syndrome. The studies indicated that 80% of patients experienced significant reductions in pruritus, with a mean reduction of -1.9 points at 48 weeks, deepening to -2.3 points at week 220. Maralixibat may provide an alternative to surgery with potential improvements in quality of life and growth parameters. The company is progressing towards its rolling NDA submission for the drug.